Skip to content

Validation of the Dayzz Digital Sleep Training App in Insomnia and Sleep Apnea

Validation of the Dayzz Digital Sleep Training App in Insomnia and Sleep Apnea

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03955120
Enrollment
125
Registered
2019-05-17
Start date
2019-01-29
Completion date
2020-12-30
Last updated
2021-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia, Sleep Apnea

Keywords

sleep disorders, cognitive and behavioral treatment, digital treatment, insomnia, sleep apnea, sleep

Brief summary

The prevalence of sleep disorders has achieved epidemic proportions in Western countries. Despite this, assessment and treatment of sleep disorders remains infrequent, unattainable, and often costly. Dayzz is aware of the need for easily accessible, user-friendly, and affordable treatment strategies for known sleep conditions. This research proposes a randomized controlled outcome study aimed to validate a, digitized, cost-effective mobile app which assesses and manages insomnia and CPAP adherence in persons with sleep apnea. The app's sleep training protocols recommend life-style and behavioral changes and tracks these changes with the aim of improving sleep and well-being. In this study, the dayzz app digital treatment protocol will be compared to the standard treatment for these sleep conditions by a sleep professional.

Interventions

BEHAVIORALDayzz mobile sleep training

1. The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties. 2. Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program. 3. Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study.

OTHERTreatment as usual

Standard medical care for specific sleep condition

Sponsors

Israel Innovation Authority
CollaboratorUNKNOWN
Dayzz Live Well Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 21-65 years of age referred to the Carmel Hospital sleep clinic and diagnosed by the clinic physician with either Sleep Apnea (referred for CPAP treatment) or Insomnia.

Exclusion criteria

* Patient age \<21 years. * Patient who is not a member of Clalit Healthcare services. * Persons with insufficient control of the English language required for adequate use of app. * Persons with insufficient experience/knowledge and/or use of digital apps/smartphones. * Persons with serious medical or psychiatric conditions. * Women who are pregnant or breastfeeding. * Nighttime shift-workers. * Persons who are unable to provide consent due to mental incapacity. * Persons referred for evaluation of sleep by Ministry of Transportation (for licensing purposes). * Persons with comorbid insomnia and sleep apnea

Design outcomes

Primary

MeasureTime frameDescription
Insomnia severity3 months to 1 yearThe Insomnia Severity Index (ISI) is a well-validated 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia over the past month (Morin, 1993). The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
Sleep quality3 months to 1 yearLikert scale of sleep quality between 1 and 10 (based on sleep diary report)
Nightly CPAP use3 months to 1 yearMinutes of wearing the CPAP mask per night (based on sleep diary report)
Excessive daytime sleepiness3 months to 1 yearThe Epworth Sleepiness Scale (ESS): The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity or their 'daytime sleepiness'.
Sleep symptom screening questionnaire3 months to 1 yearThe Dayzz Sleep Questionnaire is a digitized screening measure that assesses sleep quantity and quality and presence/risk for specific sleep disorders. It is composed of some self-rated items, assessing sleep amounts, sleep quality, excessive sleepiness, and risk factors for sleep-related breathing disorders, symptoms of insomnia and sleep/wake circadian rhythms. The questions are based on the International Classification of Sleep Disorders (3rd Edition; American Academy of Sleep Medicine) diagnostic criteria for four common categories of sleep disorders: Insomnia, Insufficient Sleep Syndrome, Sleep Apnea Disorders, and Circadian Rhythm Sleep-Wake Disorders.
Total sleep time (minutes)3 months to 1 yearsleep duration in minutes per night (based on nightly sleep diary)
Sleep onset latency (minutes)3 months to 1 yearNumber of minutes to fall asleep per night (based on nightly sleep diary)
Wake after sleep onset (minutes)3 months to 1 yearNumber of minutes awake in total per night (based on nightly sleep diary)
Sleep efficiency (percent)3 months to 1 year(Number of minutes asleep per night/number of minutes in bed per night)\*100 (based on sleep diary data)

Secondary

MeasureTime frameDescription
Insomnia-related quality of life3 months to 1 yearThe Glasgow Sleep Impact Index (GSII). Administered only to the insomnia sample. The GSII is a self-report measure which asks patients to generate, and assess, three domains of measure insomnia-related quality of life impairment. These three patient-generated areas of impairment are ranked in order of concern (1-3; i.e. 1=the most concerning impairment), and then rated on a visual analogue scale with respect to impact in the past two weeks. Patients re-rate these specified areas of impairment, post-intervention, permitting both individual and group-level analyses.
Sleep Apnea-related Quality of Life-Short form (SAQLI-SF)3 months to 1 yearThe SAQLI- SF (for sleep apnea sample only) measures the effects of sleep apnea on a person's quality of life. The questions represent four quality of life domains: Daily Activities, Social Interactions, Emotions,and Symptoms. Two total scores will be generated, which reflect the pre- and post-treatment quality of life. The total scores range between 1-14, with higher values representing poorer outcomes. No subscale scores are generated.
The WHO-5 Well-being Index (WHO-5)3 months to 1 yearThe WHO-5 Well-being Index (WHO-5) is a short, self-administered questionnaire measuring psychological well-being. It covers 5 positively worded items, related to positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interests (being interested in things). Each of the five items is rated on a 6-point Likert scale from 0 (= not present) to 5 (= constantly present). Scores are summated, with raw score ranging from 0 to 25. Then the scores are transformed to 0-100 by multiplying by 4 which provides the total score, with higher scores meaning better well-being. The scale does not generate subscale scores.
Work productivity3 months to 1 yearThe Work Productivity and Activity Impairment Questionnaire-Specific Health problem (WPAI:SHP): The WPAI is a patient-reported quantitative assessment of the amount of absenteeism, presenteeism and daily activity impairment attributable to a specific health problem (Reilly et al, 1993). WPAI:SHP outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026